Resultados de procura - Ursula A. Matulonis

Limitar resultados
  1. 1
    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential por Tarra Evans, Ursula A. Matulonis

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? por Ursula A. Matulonis, Bradley J. Monk

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  3. 3
    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies por Elizabeth K. Lee, Ursula A. Matulonis

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  4. 4
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations por Jennifer Veneris, Ursula A. Matulonis, Joyce F. Liu, Panagiotis A. Konstantinopoulos

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  5. 5
    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers

    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers por Elizabeth K. Lee, David L. Kolin, Ursula A. Matulonis, Britt Erickson

    Publicado 2025
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  6. 6
    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials por Ursula A. Matulonis, Amit M. Oza, Tony W. Ho, Jonathan A. Ledermann

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  7. 7
    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies por Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Elizabeth M. Swisher

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  8. 8
    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer por S. Percy Ivy, Joyce F. Liu, Jung‐Min Lee, Ursula A. Matulonis, Elise C. Kohn

    Publicado 2016
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  9. 9
    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines

    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines por Brian J. Druker, Keiko Okuda, Ursula A. Matulonis, Ravi Salgia, Thomas M. Roberts, JD Griffin

    Publicado 1992
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor por Emily Robinson, Ursula A. Matulonis, Percy Ivy, Suzanne Berlin, Karin Tyburski, Richard T. Penson, Benjamin D. Humphreys

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Ovarian cancer

    Ovarian cancer por Ursula A. Matulonis, Anil K. Sood, Lesley Fallowfield, Brooke E. Howitt, Jalid Sehouli, Beth Y. Karlan

    Publicado 2016
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  12. 12
    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. por Ursula A. Matulonis, Chrysoula Dosiou, GJ Freeman, Christine Lamont, Peter Mauch, L M Nadler, James D. Griffin

    Publicado 1996
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma

    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma por Elizabeth H. Stover, Colleen M. Feltmate, Ross S. Berkowitz, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health

    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health por Alexi A. Wright, Nancy L. Keating, Tracy A. Balboni, Ursula A. Matulonis, Susan D. Block, Holly G. Prigerson

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study

    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study por Melissa A. Merritt, Megan S. Rice, Mollie E. Barnard, Susan E. Hankinson, Ursula A. Matulonis, Elizabeth M. Poole, Shelley S. Tworoger

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks

    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks por Kun‐Hsing Yu, Vincent J. Hu, Feiran Wang, Ursula A. Matulonis, George L. Mutter, Jeffrey A. Golden, Isaac S. Kohane

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine por Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O’Malley, Ursula A. Matulonis, Gottfried E. Konecny

    Publicado 2023
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  18. 18
    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer

    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer por Michelle Samora, José Eduardo Levi, Sergio Nicolau, Edvane De Domenico, Ursula A. Matulonis, Audrey Tieko Tsunoda, Pâmela Perez Leite, Rafael Schmerling

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance

    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance por Raphaël Ceccaldi, Kevin W. O’Connor, Kent W. Mouw, Adam Y. Li, Ursula A. Matulonis, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells por Young Eun Choi, Chiara Battelli, Jacqueline Watson, Joyce F. Liu, Jennifer Curtis, Alexander Morse, Ursula A. Matulonis, Dipanjan Chowdhury, Panagiotis A. Konstantinopoulos

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: